IRLAB presents ISP at the CNS and Neurodegenerative Targets conference in Boston
IRLAB’s research platform, the Integrative Screening Process – ISP, is gaining increased international interest. ISP will be presented at the CNS and Neurodegenerative Targets conference in Boston, 26-27 September 2018.
IRLAB is invited to present at the conference and participates with the presentation “Evolving the Concept of Phenotypic Screening to a New Level of Data-Driven, Systems Oriented Drug Discovery”. The presentation is held by Peder Svensson, PhD – Director of Computational Chemistry & Biology, CIO. More information about the ISP is available on IRLAB’s website, www.irlab.se/isp-platform, and in the published article in ACS Chemical Neuroscience, www.bit.ly/IRLAB_ACS.
The conference aims at highlighting the latest research tools and platforms driving today’s CNS drug discovery strategies. For more information, see the conference website, www.discoverytarget.com/CNS-Neurodegenerative-Targets.
For further information
Nicholas Waters, CEO
Phone: +46 730 75 77 01
IRLAB is a research and development company, listed on Nasdaq First North Premier, focused on development of novel therapies for the treatment of neurodegenerative diseases, in particular Parkinson’s disease.
IRLAB has two clinical candidate drugs, IRL752 and IRL790, focused on medical needs in Parkinson’s disease. IRLAB also has additional programs in pre-clinical stages.
IRLAB’s research is aimed at discovery and development of new candidate drugs addressing unmet medical need in diseases of the central nervous system, using the unique and proprietary integrative screening process, ISP.
IRLAB is based in Gothenburg, Sweden. The operations are mainly carried out through the subsidiary Integrative Research Laboratories Sweden AB.
For more information, please visit www.irlab.se.